RESUMO
BACKGROUND: Canine leishmaniosis (CanL), caused by Leishmania infantum, is an important vector-borne parasitic disease in dogs with implications for human health. Despite advancements, managing CanL remains challenging due to its complexity, especially in chronic, relapsing cases. Mathematical modeling has emerged as a powerful tool in various medical fields, but its application in understanding CanL relapses remains unexplored. METHODS: This retrospective study aimed to investigate risk factors associated with disease relapse in a cohort of dogs naturally infected with L. infantum. Data from 291 repeated measures of 54 dogs meeting the inclusion criteria were included. Two logistic mixed-effects models were created to identify clinicopathological variables associated with an increased risk of clinical relapses requiring a leishmanicidal treatment in CanL. A backward elimination approach was employed, starting with a full model comprising all potential predictors. Variables were iteratively eliminated on the basis of their impact on the model, considering both statistical significance and model complexity. All analyses were conducted using R software, primarily employing the lme4 package, and applying a significance level of 5% (P < 0.05). RESULTS: This study identified clinicopathological variables associated with an increased risk of relapses requiring a leishmanicidal treatment. Model 1 revealed that for each 0.1 increase in the albumin/globulin ratio (A/G) ratio, the odds of requiring treatment decreased by 45%. Conversely, for each unit increase in the total clinical score (CS), the odds of requiring treatment increase by 22-30%. Indirect immunofluorescence antibody test (IFAT) was not a significant risk factor in model 1. Model 2, incorporating individual albumin and globulins values, showed that dogs with high IFAT titers, hyper beta-globulinemia, hypoalbuminemia, anemia, and high CS were at increased risk of relapse. Both models demonstrated a good fit and explained a substantial amount of variability in treatment decisions. CONCLUSIONS: Dogs exhibiting higher CS, dysproteinemia, anemia, and high IFAT titers are at increased risk of requiring leishmanicidal treatment upon clinical relapse in CanL. Regular monitoring and assessment of risk factors prove essential for early detection of relapses and effective intervention in CanL cases. The contrasting findings between the two models highlight the complexity of aspects influencing treatment decisions in this disease and the importance of tailored management strategies to improve outcomes for affected dogs.
Assuntos
Doenças do Cão , Leishmania infantum , Leishmaniose Visceral , Recidiva , Cães , Animais , Doenças do Cão/parasitologia , Doenças do Cão/tratamento farmacológico , Fatores de Risco , Estudos Retrospectivos , Leishmaniose Visceral/veterinária , Leishmaniose Visceral/parasitologia , Leishmaniose Visceral/tratamento farmacológico , Modelos Logísticos , Feminino , Masculino , Leishmaniose/veterinária , Leishmaniose/tratamento farmacológico , Leishmaniose/parasitologiaRESUMO
Background: Azathioprine is one of the earliest immunosuppressants prescribed for several autoimmune diseases. Yet there is a lack of research on the impact of azathioprine on pulp healing following the pulp capping procedure. Aim: This study aimed to investigate the effect of azathioprine on the healing ability of mechanically exposed dogs' dental pulps following direct pulp capping with mineral trioxide aggregate (MTA), bio-aggregates (BA), and Calcium hydroxide (Ca(OH)2). Methods: Four mongrel dogs were randomly assigned to two groups (two dogs/30 teeth in each group): immunosuppressed (group I) and control (group II). Group I received azathioprine for two months before surgical treatments and until the dogs were euthanized. Fifteen class V buccal cavities were performed in each dog. Each group was randomly divided into three subgroups (10 teeth each) based on the pulp capping substance. The pulps in subgroups A, B, and C were immediately capped with MTA, BA, and Ca(OH)2, respectively. Inflammation and dentine bridge development were histopathologically evaluated and scored at one and two months. The data were statistically analyzed. Results: The immunosuppressed group exhibited statistically greater inflammatory cell count and decreased dentine bridge thickness, compared to the control group in all subgroups (p < 0.05). Conclusion: Azathioprine has an adverse effect on the healing of exposed dogs' dental pulp following direct pulp capping with MTA, BA, and Ca(OH)2. Therefore, patients using azathioprine as an immunosuppressive medication may experience delayed healing of mechanically exposed pulps following capping with MTA, BA, or Ca(OH)2.
Assuntos
Azatioprina , Compostos de Cálcio , Hidróxido de Cálcio , Capeamento da Polpa Dentária , Imunossupressores , Óxidos , Silicatos , Animais , Cães , Azatioprina/farmacologia , Azatioprina/uso terapêutico , Capeamento da Polpa Dentária/veterinária , Óxidos/farmacologia , Imunossupressores/uso terapêutico , Imunossupressores/farmacologia , Silicatos/farmacologia , Compostos de Cálcio/farmacologia , Hidróxido de Cálcio/farmacologia , Hidróxido de Cálcio/uso terapêutico , Doenças do Cão/tratamento farmacológico , Compostos de Alumínio/farmacologia , Polpa Dentária/efeitos dos fármacos , Combinação de Medicamentos , Masculino , Cicatrização/efeitos dos fármacos , Agentes de Capeamento da Polpa Dentária e Pulpectomia/farmacologia , FemininoRESUMO
The present investigation aimed to quantitatively assess the level of parasitemia in dogs using qPCR.The dogs selected for this study were infected with the haemoprotozoan parasite Babesia gibsoni. In the study, dogs diagnosed with babesiosis were divided into two groups (n = 12) and subjected to distinct treatment strategies. The first group received clindamycin-metronidazole-doxycycline (CMD) therapy, while the second group was treated with a combination of buparvaquone-azithromycin (BPV-AZM). The level of parasitemia in the infected dogs was determined using an absolute quantification-based qPCR method. This assessment was conducted both prior to initiating the treatment and on the 10th day following the commencement of the treatment protocols. On the tenth day after the initiation of treatment, the CMD group exhibited a lower level of parasitemia in comparison to the BPV-AZM group. In the CMD treated groups, the mean parasitemia decreased from 4.9E + 06 to 3.4E + 06, indicating a reduction in parasitic load. Conversely, in the BPV-AZM treatment groups, the mean parasitemia increased from 1.62E + 06 to 2.87E + 06, suggesting an increase in parasitic load. On the 10th day, the CMD-treated group demonstrated a statistically significant decline in the level of parasitemia, with a P-value of ≤0.001. This indicates a strong and significant reduction in parasitic load following the CMD treatment. Therefore, the absolute quantification-based qPCR method could effectively assess the initial treatment response by measuring the level of parasitemia.
Assuntos
Babesia , Babesiose , Clindamicina , Doenças do Cão , Carga Parasitária , Parasitemia , Reação em Cadeia da Polimerase em Tempo Real , Animais , Cães , Doenças do Cão/parasitologia , Doenças do Cão/diagnóstico , Doenças do Cão/tratamento farmacológico , Reação em Cadeia da Polimerase em Tempo Real/métodos , Babesia/genética , Babesia/isolamento & purificação , Parasitemia/parasitologia , Parasitemia/veterinária , Babesiose/parasitologia , Babesiose/diagnóstico , Clindamicina/uso terapêutico , Carga Parasitária/métodos , Doxiciclina/uso terapêutico , Azitromicina/uso terapêutico , Metronidazol/uso terapêutico , Antiprotozoários/uso terapêutico , NaftoquinonasRESUMO
Many of the reproductive tract infections in the bitches are caused by bacteria that can normally be present on the vaginal mucosa. These bacteria also might have an important role as the cause responsible for pregnancy loss and fetal deaths. The choice of antibiotic therapy for the pregnant animal is narrow and represents a severe problem in veterinary practice, especially due to increased antimicrobial resistance. Due to incorrect antimicrobials use in breeding kennels, the aim of the present study was to assess the occurrence of the bacterial flora isolated from the pregnant bitches and their antibiotic sensitivity. The study was carried out at the private Veterinary clinic in Novi Sad, Serbia. The vaginal swabs were taken from 60 bitches diagnosed with pregnancy and were sent to be laboratory tested. Based on the results, the most common isolated pathogens were Staphylococcus pseudintermedius (20%) and beta-hemolytic streptococci (18.33%). Furthermore, significant resistance to antibiotics from beta-lactams group was detected. It is of particular importance that antimicrobial treatment be evidence based in order to reduce the overuse of antimicrobials due to increased concern regarding antimicrobial resistance.
Assuntos
Antibacterianos , Doenças do Cão , Farmacorresistência Bacteriana , Staphylococcus , Vagina , Animais , Feminino , Cães , Gravidez , Vagina/microbiologia , Doenças do Cão/microbiologia , Doenças do Cão/epidemiologia , Doenças do Cão/tratamento farmacológico , Antibacterianos/farmacologia , Staphylococcus/efeitos dos fármacos , Complicações Infecciosas na Gravidez/veterinária , Complicações Infecciosas na Gravidez/microbiologia , Complicações Infecciosas na Gravidez/epidemiologia , Prevalência , Streptococcus/efeitos dos fármacos , Streptococcus/isolamento & purificação , Sérvia/epidemiologia , Testes de Sensibilidade MicrobianaRESUMO
The use of tyrosine kinase inhibitors (TKI) has been growing in veterinary oncology and in the past few years several TKI have been tested in dogs. However, different from human medicine, we lack strategies to select patients to be treated with each TKI. Therefore, this study aimed to screen different tumor subtypes regarding TKI target immunoexpression as a predictor strategy to personalize the canine cancer treatment. It included 18 prostatic carcinomas, 36 soft tissue sarcomas, 20 mammary gland tumors, 6 urothelial bladder carcinomas, and 7 tumors from the endocrine system. A total of 87 patients with paraffin blocks were used to perform immunohistochemistry (IHC) of human epidermal growth factor receptor 2 (HER-2), epidermal growth factor receptors 1 (EGFR1), vascular endothelial growth factor receptor 2 (VEGFR-2), platelet derived growth factor receptor beta (PDGFR-ß), c-KIT, and extracellular signal-regulated kinase 1/2 (ERK1/ERK2). The immunohistochemical screening revealed a heterogeneous protein expression among histological types with mesenchymal tumors showing the lowest expression level and carcinomas the highest expression. We have demonstrated by IHC screening that HER2, EGFR1, VEGFR-2, PDGFR-ß and ERK1/ERK2 are commonly overexpressed in dogs with different carcinomas, and KIT expression is considered relatively low in the analyzed samples.
Assuntos
Doenças do Cão , Imuno-Histoquímica , Cães , Animais , Doenças do Cão/metabolismo , Doenças do Cão/tratamento farmacológico , Doenças do Cão/patologia , Masculino , Feminino , Neoplasias/metabolismo , Neoplasias/tratamento farmacológico , Neoplasias/veterinária , Neoplasias/patologia , Receptor beta de Fator de Crescimento Derivado de Plaquetas/metabolismo , Receptores Proteína Tirosina Quinases/metabolismo , Inibidores de Proteínas Quinases/uso terapêutico , Inibidores de Proteínas Quinases/farmacologia , Biomarcadores Tumorais/metabolismo , Receptor ErbB-2/metabolismo , Proteínas Proto-Oncogênicas c-kit/metabolismo , Receptores ErbB/metabolismo , Receptor 2 de Fatores de Crescimento do Endotélio Vascular/metabolismo , HumanosRESUMO
Leptospirosis is a widespread zoonosis in tropical regions and it is not frequently recognised in developed countries. We report a case of leptospirosis transmitted from a pet dog. A middle-aged woman was referred to our emergency department with a 7-day history of fever and diarrhoea. She presented with hypotension, tachycardia, grasping pain in the entire muscle and petechiae. A detailed medical interview revealed that her pet dog had been to the veterinarian 1 month earlier with similar symptoms. We treated her with intravenous antibiotics. The patient's diagnosis of leptospirosis was confirmed by serological testing and the detection of DNA in her urine. We contacted the veterinarian and shared the information. We found that the dog had suffered from leptospirosis based on serological testing. We emphasise the possibility of leptospirosis being transmitted from pet dogs. Persistent suspicion of leptospirosis will contribute to its diagnosis and improved public health.
Assuntos
Antibacterianos , Doenças do Cão , Leptospirose , Animais de Estimação , Leptospirose/diagnóstico , Leptospirose/tratamento farmacológico , Leptospirose/transmissão , Leptospirose/veterinária , Cães , Humanos , Animais , Feminino , Doenças do Cão/diagnóstico , Doenças do Cão/microbiologia , Doenças do Cão/tratamento farmacológico , Pessoa de Meia-Idade , Antibacterianos/uso terapêutico , Animais de Estimação/microbiologia , Zoonoses/diagnóstico , Zoonoses/transmissão , Zoonoses/microbiologiaRESUMO
A 3-year-old castrated male golden retriever was presented for evaluation of 2 cutaneous masses along the abdominal midline and a 6-month history of progressive lethargy and inappetence. Two years earlier, the dog underwent a gastrotomy to retrieve a foreign object and recovered uneventfully. Fluid aspirated from the lesions was culture-negative for aerobic and anaerobic bacterial growth. Abdominal ultrasound demonstrated a large intra-abdominal mass with apparent communication with the cutaneous lesion, along with gossypiboma from the previous laparotomy. Neoplasia or a sterile abscess were suspected. Exploratory laparotomy was performed and revealed that the intra-abdominal mass was adhered to the abdominal midline and the greater curvature of the stomach. The masses and affected portions of the body wall and stomach were resected and histopathology was consistent with phaeohyphomycosis. Antifungal therapy with voriconazole (6.3 mg/kg, PO, q12h) was initiated. At 1 mo after surgery, all clinical signs had resolved. At 4 and 7 mo after surgery, the dog continued to thrive despite 2 small masses, seen on abdominal ultrasound imaging on the intra-abdominal midline, suggestive of reoccurrence. Continued voriconazole therapy was administered in lieu of further surgical excision. One year after surgery, the masses were no longer present on ultrasonographic evaluation. Phaeohyphomycosis is a rare, opportunistic fungal infection that typically affects the dermis and subcutis of immunocompromised dogs. This is the first report of phaeohyphomycosis in an immunocompetent dog and involving the dermis, subcutis, and abdominal viscera. Key clinical message: This case adds to the very limited literature on phaeohyphomycosis in dogs and illustrates that surgery could be a risk factor for infection, even in dogs with no known underlying disease or immunodeficiency.
Phéohyphomycose cutanée et viscérale chez un golden retriever immunocompétentUn golden retriever mâle castré de 3 ans a été présenté pour évaluation de 2 masses cutanées le long de la ligne médiane abdominale et d'un historique de léthargie et d'inappétence progressive depuis 6 mois. Deux ans plus tôt, le chien avait subi une gastrotomie pour récupérer un objet étranger et s'était rétabli sans incident. Le liquide aspiré des lésions était négatif en culture pour la croissance bactérienne aérobie et anaérobie. L'échographie abdominale a mis en évidence une masse intra-abdominale importante avec une communication apparente avec la lésion cutanée, ainsi qu'un gossyibome issu de la laparotomie précédente. Un néoplasme ou un abcès stérile ont été suspectés. Une laparotomie exploratoire a été réalisée et a révélé que la masse intra-abdominale adhérait à la ligne médiane abdominale et à la grande courbure de l'estomac. La masse et les parties affectées de la paroi corporelle et de l'estomac ont été réséquées et l'histopathologie était compatible avec une phaeohyphomycose. Un traitement antifongique par voriconazole (6,3 mg/kg, PO, toutes les 12 heures) a été instauré. Un mois après l'intervention chirurgicale, tous les signes cliniques avaient disparu. À 4 et 7 mois après l'intervention chirurgicale, le chien a continué à bien allé malgré 2 petites masses, observées à l'échographie abdominale sur la ligne médiane intra-abdominale, évocatrices d'une réapparition. La poursuite du traitement par le voriconazole a été administrée au lieu d'une nouvelle excision chirurgicale. Un an après l'intervention chirurgicale, les masses n'étaient plus présentes à l'évaluation échographique. La phaeohyphomycose est une infection fongique rare et opportuniste qui affecte généralement le derme et le sous-cutané des chiens immunodéprimés. Il s'agit du premier rapport de phaeohyphomycose chez un chien immunocompétent et impliquant le derme, le tissu sous-cutané et les viscères abdominaux.Message clinique clé :Ce cas s'ajoute à la littérature très limitée sur la phaeohyphomycose chez le chien et illustre que la chirurgie pourrait être un facteur de risque d'infection, même chez les chiens sans maladie sous-jacente ou immunodéficience connue.(Traduit par Dr Serge Messier).
Assuntos
Antifúngicos , Doenças do Cão , Feoifomicose , Animais , Cães , Masculino , Doenças do Cão/microbiologia , Doenças do Cão/cirurgia , Doenças do Cão/tratamento farmacológico , Feoifomicose/veterinária , Feoifomicose/tratamento farmacológico , Feoifomicose/diagnóstico , Antifúngicos/uso terapêutico , Voriconazol/uso terapêutico , Imunocompetência , Dermatomicoses/veterinária , Dermatomicoses/diagnósticoRESUMO
BACKGROUND: Romiplostim, a thrombopoietin analog, is commonly used to treat immune-mediated thrombocytopenia (ITP) in humans, but its use in dogs remains limited. OBJECTIVES: Evaluate the effects and adverse events of romiplostim administration in dogs with thrombocytopenia caused by various underlying diseases. ANIMALS: Forty-two client-owned dogs with naturally occurring thrombocytopenia at 2 referral animal hospitals. METHODS: Retrospective, multi-institutional analysis to evaluate the outcomes of romiplostim treatment in dogs. RESULTS: Among the dogs treated with romiplostim, 27 experienced an increase in platelet count and 26 maintained a platelet count within the reference range. Platelet count improvement was observed in various conditions: primary ITP (90%, n = 18/20), pancytopenia of unknown etiology (42.9%, n = 3/7), chemotherapy-induced thrombocytopenia (50%, n = 3/6), babesiosis (100%, n = 1/1), radiotherapy-induced thrombocytopenia (0%, n = 0/1), and disseminated intravascular coagulopathy (33.3%, n = 2/6). The median time for platelet recovery (>50 000/µL) after romiplostim administration was 4 days, and the median time for platelet count normalization was 7 days. Median hospitalization time for the improvement group (I) was 5 days. The survival-to-discharge rates were 85%, 40%, and 28.6% for dogs with primary ITP, secondary thrombocytopenia, and thrombocytopenia of unknown etiology, respectively. CONCLUSIONS AND CLINICAL IMPORTANCE: Romiplostim is a well-tolerated and promising treatment for primary ITP in dogs, suggesting its potential as a valuable therapeutic option for dogs with thrombocytopenia caused by various underlying conditions. These findings emphasize the need for further research to optimize romiplostim dosing and understand its role in treating secondary thrombocytopenia and pancytopenia of unknown etiology.
Assuntos
Doenças do Cão , Receptores Fc , Proteínas Recombinantes de Fusão , Trombocitopenia , Trombopoetina , Cães , Animais , Trombopoetina/uso terapêutico , Receptores Fc/uso terapêutico , Proteínas Recombinantes de Fusão/uso terapêutico , Proteínas Recombinantes de Fusão/efeitos adversos , Proteínas Recombinantes de Fusão/administração & dosagem , Doenças do Cão/tratamento farmacológico , Estudos Retrospectivos , Feminino , Trombocitopenia/veterinária , Trombocitopenia/tratamento farmacológico , Masculino , Contagem de Plaquetas/veterinária , Resultado do Tratamento , Púrpura Trombocitopênica Idiopática/tratamento farmacológico , Púrpura Trombocitopênica Idiopática/veterináriaRESUMO
BACKGROUND: The high doses of radioiodine-131 (131I) and, subsequently, the high radioactive burden for dog and environment warrants optimization of 131I therapy in dogs with thyroid carcinoma (TC). HYPOTHESIS/OBJECTIVES: To evaluate the effect of a revised protocol with recombinant human thyroid stimulating hormone (rhTSH) on tumor radioactive iodine uptake (RAIU) in dogs with TC. ANIMALS: Nine client-owned dogs diagnosed with TC. METHODS: A prospective cross-over study in which tumor RAIU was calculated and compared at 8 hours (8h-RAIU) and 24 hours (24h-RAIU) after injection of radioactive iodine-123 (123I), once with and once without rhTSH (ie, 250 µg, IM, 24 and 12 hours before 123I) in each dog. Simultaneously, serum total thyroxine (TT4) and TSH were measured at baseline (T0), and 6 (T6), 12 (T12), 24 (T24), and 48 hours (T48) after the first rhTSH administration. RESULTS: Tumor RAIU was significantly higher at 24 hours with rhTSH compared to no rhTSH (mean difference = 8.85%, 95% CI of [1.56; 16.14]; P = .03), while this was non-significant at 8 hours (mean difference = 4.54%, 95% CI of [0.35; 8.73]; P = .05). A significant change of serum TT4 (median difference T24 - T0 = 35.86 nmol/L, interquartile range [IQR] = 15.74 nmol/L) and TSH (median difference T24 - T0 = 1.20 ng/mL, IQR = 1.55 ng/mL) concentrations occurred after administration of rhTSH (P < .001). CONCLUSIONS AND CLINICAL IMPORTANCE: Recombinant human TSH could optimize 131I treatment in dogs with TC by increasing tumor RAIU and thus 131I treatment efficacy.
Assuntos
Estudos Cross-Over , Doenças do Cão , Radioisótopos do Iodo , Proteínas Recombinantes , Neoplasias da Glândula Tireoide , Tireotropina , Animais , Cães , Neoplasias da Glândula Tireoide/veterinária , Neoplasias da Glândula Tireoide/radioterapia , Neoplasias da Glândula Tireoide/tratamento farmacológico , Radioisótopos do Iodo/uso terapêutico , Doenças do Cão/tratamento farmacológico , Doenças do Cão/radioterapia , Tireotropina/uso terapêutico , Tireotropina/farmacologia , Feminino , Masculino , Estudos Prospectivos , Proteínas Recombinantes/uso terapêutico , Proteínas Recombinantes/farmacologia , Proteínas Recombinantes/administração & dosagem , Tiroxina/uso terapêuticoRESUMO
BACKGROUND: Dogs with lymphoma that fail cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (CHOP) before completion of their protocol are commonly thought to have poor long-term outcome, but no previous studies have evaluated the effect of early relapse on progression-free interval (PFI) or overall survival time (OST) for patients undergoing rescue chemotherapy. OBJECTIVE: Correlate rescue treatment outcomes in dogs with multicentric lymphoma with outcomes after 1st-line CHOP chemotherapy. METHODS: Data were collected from 6 previous retrospective or prospective studies in 187 dogs with multicentric lymphoma that received 1st-line CHOP chemotherapy and then received either lomustine (CCNU), L-asparaginase and prednisone (LAP), or rabacfosadine (RAB, Tanovea), with or without prednisone or L-asparaginase. RESULTS: The PFI after initiation of CHOP chemotherapy was significantly associated with response rate postprogression, PFI, and postrescue survival time (ST) for both rescue protocols. Immunophenotype (B- vs T-cell) was not significantly associated with response, PFI or OST for LAP but was significantly associated with response and PFI for RAB. CONCLUSION: Dogs that experience short PFI during or after 1st-line CHOP chemotherapy had lower response rates to rescue treatment, with shorter PFI and ST. Immunophenotype did not significantly affect outcome with LAP but was associated with PFI for RAB.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica , Ciclofosfamida , Doenças do Cão , Doxorrubicina , Linfoma , Prednisona , Vincristina , Animais , Cães , Doenças do Cão/tratamento farmacológico , Vincristina/uso terapêutico , Ciclofosfamida/uso terapêutico , Ciclofosfamida/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Prednisona/uso terapêutico , Prednisona/administração & dosagem , Doxorrubicina/uso terapêutico , Feminino , Masculino , Linfoma/veterinária , Linfoma/tratamento farmacológico , Asparaginase/uso terapêutico , Resultado do Tratamento , Estudos Retrospectivos , Lomustina/uso terapêutico , Progressão da Doença , Estudos Prospectivos , Alanina/análogos & derivados , PurinasRESUMO
OBJECTIVE: To describe the clinical course and treatment of 3 dogs with peripheral vasopressor extravasation. CASE SERIES SUMMARY: Although vasopressor extravasation (VE) is a well-documented complication in human medicine, literature describing VE and its management in veterinary patients is sparse. VE increases patient morbidity by causing local tissue injury and necrosis. The gold standard treatment for VE, phentolamine, has been periodically limited in supply in human medicine and is not consistently available for use in veterinary medicine. An alternative protocol proposed for use in people with VE combines topical nitroglycerin application with subcutaneous terbutaline infiltration. In this report, a treatment protocol utilizing these therapies was used to treat 3 dogs with VE and secondary tissue injury. NEW OR UNIQUE INFORMATION PROVIDED: This report describes 3 cases of VE-induced tissue injury in dogs. In addition, this report describes the use of perivascular terbutaline infiltration and topical nitroglycerin application as therapeutic management for VE in dogs.
Assuntos
Administração Tópica , Doenças do Cão , Nitroglicerina , Terbutalina , Animais , Cães , Nitroglicerina/administração & dosagem , Nitroglicerina/uso terapêutico , Terbutalina/administração & dosagem , Terbutalina/uso terapêutico , Doenças do Cão/tratamento farmacológico , Masculino , Feminino , Extravasamento de Materiais Terapêuticos e Diagnósticos/veterinária , Extravasamento de Materiais Terapêuticos e Diagnósticos/tratamento farmacológico , Injeções Subcutâneas/veterinária , Vasoconstritores/administração & dosagem , Vasoconstritores/uso terapêutico , Pomadas , Vasodilatadores/administração & dosagem , Vasodilatadores/uso terapêuticoRESUMO
Left ventricular dysfunction in dogs after the administration of doxorubicin (DOX) has been extensively examined. However, the effects of DOX on right ventricular (RV) function remain unknown. Therefore, the present study investigated whether the chemotherapy treatment with DOX decreases RV function. Twelve dogs (five with multicentric lymphoma, four with hemangiosarcoma, two with thyroid cancer, and one with lung adenocarcinoma) that received at least two doses of DOX were prospectively enrolled. Echocardiography and the measurement of troponin I were performed prior to each administration of DOX and approximately one month after the last administration. Right ventricular function was assessed by the RV fractional area change and RV Tei index. Two (n=4), three (n=3), four (n=3), and five (n=2) doses of DOX were administered. While no significant differences were observed in the RV fractional area change, the RV Tei index was significantly impaired after two doses of DOX. Troponin I level significantly increased after four doses. Cumulative doses of DOX correlated with the RV Tei index (r=0.77, P<0.001). The present results demonstrated that the chemotherapy treatment with DOX decreased RV function in a dose-dependent manner in dogs.
Assuntos
Antibióticos Antineoplásicos , Doenças do Cão , Doxorrubicina , Ecocardiografia , Troponina I , Animais , Cães , Doxorrubicina/administração & dosagem , Doenças do Cão/tratamento farmacológico , Masculino , Feminino , Antibióticos Antineoplásicos/uso terapêutico , Troponina I/sangue , Ecocardiografia/veterinária , Função Ventricular Direita/efeitos dos fármacos , Disfunção Ventricular Direita/veterinária , Disfunção Ventricular Direita/tratamento farmacológico , Linfoma/veterinária , Linfoma/tratamento farmacológico , Estudos Prospectivos , Hemangiossarcoma/veterinária , Hemangiossarcoma/tratamento farmacológicoRESUMO
Furuncular myiasis due to Dermatobia hominis is the second most common skin diseases in dogs that live in tropical climates in Central and South America, causing discomfort and injuring in the connective tissue of the affected dog. Therefore, the objective of the study was to evaluate the effectiveness of Afoxolaner (Nexgard®) in the treatment of canine furuncular myiasis. Twenty-five dogs naturally infested with D. hominis were selected and received a single oral dose of 2.5 mg/kg body weight of Afoxolaner (NexGard®). Larval infestations were classified as light (< 2 larvae), moderate (2 to 5 larvae) and severe (> 5 larvae), according to the number of larvae found in the wound. Twenty-four hours post-treatment, infested lesions were inspected, and all larvae were mechanically removed from the lesion site. All removed larvae were identified as D. hominis larvae and were found dead within 24 h after treatment, demonstrating 100% larvicidal efficacy of Afoxolaner against D. hominis larvae.
Assuntos
Dípteros , Doenças do Cão , Larva , Miíase , Naftalenos , Animais , Miíase/veterinária , Miíase/tratamento farmacológico , Miíase/parasitologia , Cães , Dípteros/efeitos dos fármacos , Doenças do Cão/tratamento farmacológico , Doenças do Cão/parasitologia , Larva/efeitos dos fármacos , Naftalenos/uso terapêutico , Naftalenos/administração & dosagem , Naftalenos/farmacologia , Masculino , Feminino , Isoxazóis/administração & dosagem , Isoxazóis/uso terapêutico , Inseticidas/uso terapêutico , Inseticidas/administração & dosagem , Inseticidas/farmacologia , Resultado do TratamentoRESUMO
Chemoprophylactic prevention of veterinary heartworm disease in companion animals, caused by the vector-borne nematode parasite Dirofilaria immitis, is a multi-billion-dollar global market. Experimental use of cats and dogs in preclinical heartworm drug testing is increasing due to evolving drug-resistance to frontline macrocyclic lactones and renewed investment in alternative preventative drug research. We and others recently published data demonstrating proof-of-concept of utilising lymphopenic severe-combined immunodeficient (SCID) or Recombination Activating Gene (RAG)2 deficient mice with additional knockout of the IL-2/7 receptor gamma chain (γc) as alternative preventative drug screening research models of dirofilariasis. Here we summarise the current knowledge of candidate immunodeficient mouse models tested, including a comparison of susceptibility using different background strains of mice, different D. immitis isolates, following use of anti-inflammatory treatments to further suppress residual innate immunity, and efficacies achieved against different reference anthelmintics. We supplement this precis with new data on treatment response to the veterinary anthelmintic, oxfendazole, and initial evaluation of D. immitis susceptibility in CB.17 SCID and C57BL/6 RAG2 -/-γc -/- mice. We conclude that in addition to NSG and NXG mice, RAG2 -/-γc -/- mice on either a BALB/c or C57BL/6 background offer an alternative screening model option, widening access to academic and commercial laboratories wishing to pursue initial rapid in vivo drug screening whilst avoiding potentially unnecessary cat or dog testing.
Assuntos
Dirofilariose , Modelos Animais de Doenças , Camundongos SCID , Animais , Cães , Gatos , Camundongos , Dirofilariose/prevenção & controle , Dirofilariose/tratamento farmacológico , Dirofilaria immitis/efeitos dos fármacos , Dirofilaria immitis/imunologia , Doenças do Gato/prevenção & controle , Doenças do Gato/parasitologia , Doenças do Gato/tratamento farmacológico , Doenças do Gato/imunologia , Doenças do Cão/prevenção & controle , Doenças do Cão/parasitologia , Doenças do Cão/tratamento farmacológico , Anti-Helmínticos/uso terapêutico , Avaliação Pré-Clínica de MedicamentosRESUMO
BACKGROUND: Many clinicians prescribe antifungal agents to treat canine otitis externa (OE). However, studies evaluating the antifungal effects of N-acetylcysteine (NAC) and its combinations are limited. HYPOTHESIS/OBJECTIVES: The aim of this study was to evaluate the antifungal effects of NAC alone and in combination with other antifungal agents against Malassezia pachydermatis isolated from canine OE. MATERIALS AND METHODS: M. pachydermatis samples were collected from 13 dogs with OE. The final concentration of the inoculum suspensions of M. pachydermatis was 1-5 × 106 colony forming units/mL. The concentrations of the test compounds ketoconazole (KTZ), terbinafine (TER), nystatin (NYS) and NAC were 0.02-300 µg/mL, 0.04-80 µg/mL, 0.16-40 µg/mL and 1.25-20 mg/mL, respectively. The minimum inhibitory concentration (MIC) was measured to evaluate the susceptibility of the M. pachydermatis to KTZ, TER, NYS and NAC. The checkerboard testing method and fractional inhibitory concentration index were used to evaluate the effect of NAC in combination with KTZ, TER and NYS against M. pachydermatis. RESULTS: The MIC90 values of M. pachydermatis were 4.6875-9.375 µg/mL, 1.25 µg/mL, 5-10 µg/mL and 10 mg/mL for KTZ, TER, NYS and NAC, respectively. The synergistic effects of KTZ, TER and NYS with NAC were identified in 0/13, 2/13 and 0/13 isolates, respectively. CONCLUSIONS AND CLINICAL RELEVANCE: NAC had an antifungal effect against M. pachydermatis but did not exert synergistic effects when used with KTZ, TER and NYS. Thus, the use of NAC alone as a topical solution could be considered an effective treatment option for canine OE involving M. pachydermatis.
Assuntos
Acetilcisteína , Antifúngicos , Doenças do Cão , Quimioterapia Combinada , Malassezia , Testes de Sensibilidade Microbiana , Otite Externa , Animais , Cães , Malassezia/efeitos dos fármacos , Otite Externa/veterinária , Otite Externa/tratamento farmacológico , Otite Externa/microbiologia , Doenças do Cão/tratamento farmacológico , Doenças do Cão/microbiologia , Antifúngicos/farmacologia , Acetilcisteína/farmacologia , Quimioterapia Combinada/veterinária , Testes de Sensibilidade Microbiana/veterinária , Masculino , FemininoRESUMO
This study aimed to investigate how the presence of co-morbid conditions influenced antimicrobial usage as presumptive prophylaxis for suspected bacteremia in dogs and cats undergoing dental treatments at primary care veterinary clinics in the United States. In 2020, data was collected from 1076 veterinary clinics across 44 US states. A total of 681,541 general anesthesia dental procedures were conducted on 592,472 dogs and 89,069 cats. This revealed that systemic antimicrobials were administered in 8.8% of dog procedures and 7.8% of cat procedures in the absence of concurrent periodontal disease or extractions. Cefpodoxime, clindamycin, and amoxicillin-clavulanate were the most frequently used antimicrobials in dogs, while cefovecin, amoxicillin-clavulanate, and clindamycin topped the list for cats. Dogs with cardiovascular, hepato-renal, and endocrine co-morbidities, as well as those undergoing concurrent removal of cutaneous or subcutaneous neoplasia, displayed higher antimicrobial use. Similarly, cats with endocrine or hepato-renal disease, retroviral infection (i.e., feline leukemia virus (FeLV), feline immunodeficiency virus (FIV)), and concurrent removal of cutaneous or subcutaneous neoplasia exhibited increased antimicrobial use. Dogs with hepato-renal abnormalities had longer treatment durations compared to those without (10.1 vs. 9.6 days). Conversely, cats with concurrent removal of cutaneous or subcutaneous neoplasia had shorter durations of treatment as compared to those that did not have this procedure performed (8.4 vs 9.2 days). The findings of this study underscore the necessity for further research and collaboration within the veterinary community to develop evidence-based guidelines, promoting responsible antimicrobial use, and advancing the field of veterinary dentistry for enhanced patient outcomes.
Assuntos
Doenças do Gato , Animais , Cães , Gatos , Estados Unidos/epidemiologia , Doenças do Gato/tratamento farmacológico , Comorbidade , Antibacterianos/uso terapêutico , Atenção Primária à Saúde , Doenças do Cão/tratamento farmacológico , Doenças do Cão/epidemiologia , Bacteriemia/tratamento farmacológico , Assistência Odontológica , Anti-Infecciosos/uso terapêuticoRESUMO
An 11-year-old neutered male large crossbreed dog was presented for investigation because of a 10-day history of progressive lethargy, hyporexia, and pyrexia. Physical and dermatological examinations were unremarkable. Blood biochemical analysis identified a marked total and ionized hypercalcemia and increased C-reactive protein concentration. Bicavitary computed tomography screening for causes of the dog's clinical and biochemical abnormalities identified a diffuse panniculitis. Histopathological examination of full-thickness skin biopsies was consistent with pyogranulomatous inflammation. Extensive histochemical staining revealed no infectious etiology. Complete clinical and biochemical remissions were observed after starting immunosuppressive, followed by tapering, doses of prednisolone, supporting an immune-mediated etiology. Key clinical message: Sterile, immune-mediated pyogranulomatous inflammation should remain a differential diagnosis for hypercalcemia in dogs. Significant dermatological disease may occur without visible abnormalities.
Panniculite pyogranulomateuse à médiation immunitaire avec hypercalcémie chez un chienUn grand chien croisé mâle castré de 11 ans a été présenté pour examen en raison d'antécédents de léthargie progressive, d'hyporexie et de pyrexie depuis 10 jours. Les examens physiques et dermatologiques étaient sans particularité. L'analyse biochimique du sang présentait une hypercalcémie totale et ionisée marquée et une concentration accrue de protéine C-réactive. Le dépistage par tomodensitométrie bicavitaire des causes des anomalies cliniques et biochimiques du chien a identifié une panniculite diffuse. L'examen histopathologique des biopsies cutanées de pleine épaisseur était compatible avec une inflammation pyogranulomateuse. Un examen par coloration histochimique extensive n'a révélé aucune étiologie infectieuse. Les rémissions cliniques et biochimiques complètes ont été observées après le début du traitement immunosuppresseur, suivies d'une diminution progressive des doses de prednisolone, confirmant une étiologie à médiation immunitaire.Message clinique clé:L'inflammation pyogranulomateuse stérile à médiation immunitaire doit rester un diagnostic différentiel de l'hypercalcémie chez le chien. Une maladie dermatologique importante peut survenir sans anomalies visibles.(Traduit par Dr Serge Messier).
Assuntos
Doenças do Cão , Hipercalcemia , Paniculite , Animais , Cães , Doenças do Cão/diagnóstico , Doenças do Cão/tratamento farmacológico , Doenças do Cão/patologia , Masculino , Paniculite/veterinária , Paniculite/diagnóstico , Hipercalcemia/veterinária , Prednisolona/uso terapêutico , Imunossupressores/uso terapêuticoRESUMO
A 5-year-old spayed female mixed-breed dog was referred to the Atlantic Veterinary College (Charlottetown, Prince Edward Island) because of a 7-month history of intermittent pink, mucoid, vulvar discharge. The dog was imported from the Bahamas at 3.5 y of age and had a history of transmissible venereal tumor (TVT) of the vulva that was successfully treated with a course of vincristine chemotherapy. Complete remission was achieved with a disease-free interval of 6 mo before clinical signs recurred. Abdominal ultrasound and CT scan identified a large caudal abdominal mass thought to arise from the uterine stump. An exploratory laparotomy was performed and the mass grossly excised. Histopathology was consistent with a poorly differentiated round cell tumor, and immunohistochemical analysis confirmed TVT as the most likely diagnosis. No further treatment was carried out. Repeat abdominal ultrasound at 4 mo after surgery showed no evidence of mass recurrence. At 8 mo after surgery, the dog was reported to be doing well clinically. Key clinical message: Transmissible venereal tumor should be considered as a differential diagnosis for masses arising from the deep genital tissues of dogs in cases where there is a history of previous TVT. Transmissible venereal tumor should be considered even in dogs that have had complete resolution of a primary mass after chemotherapy.
Tumeur vénérienne transmissible du moignon utérin à la suite d'une chimiothérapie réussie chez un chien croisé de 5 ans.Une chienne de race mixte de 5 ans, stérilisée, a été référée au Atlantic Veterinary College (Charlottetown, Île-du-Prince-Édouard) en raison d'antécédents de pertes vulvaires roses, mucoïdes et intermittentes depuis 7 mois. Le chien a été importé des Bahamas à l'âge de 3,5 ans et avait des antécédents de tumeur vénérienne transmissible (TVT) de la vulve qui a été traitée avec succès par une chimiothérapie à la vincristine. Une rémission complète a été obtenue avec un intervalle sans maladie de 6 mois avant la réapparition des signes cliniques. L'échographie abdominale et la tomodensitométrie ont identifié une grosse masse abdominale caudale qui proviendrait du moignon utérin. Une laparotomie exploratoire a été réalisée et la masse excisée. L'histopathologie était compatible avec une tumeur à cellules rondes peu différenciée et l'analyse immunohistochimique a confirmé la TVT comme le diagnostic le plus probable. Aucun autre traitement n'a été effectué. Une échographie abdominale répétée 4 mois après la chirurgie n'a montré aucun signe de récidive massive. Huit mois après l'opération, la chienne se portait bien cliniquement.Message clinique clé:Les tumeurs vénériennes transmissibles doivent être considérées comme un diagnostic différentiel pour les masses provenant des tissus génitaux profonds des chiens dans les cas où il existe des antécédents de TVT. Une tumeur vénérienne transmissible doit être envisagée même chez les chiens dont la masse primaire a complètement disparu après chimiothérapie.(Traduit par Dr Serge Messier).
Assuntos
Doenças do Cão , Tumores Venéreos Veterinários , Animais , Cães , Feminino , Doenças do Cão/tratamento farmacológico , Doenças do Cão/cirurgia , Tumores Venéreos Veterinários/tratamento farmacológico , Tumores Venéreos Veterinários/patologia , Vincristina/uso terapêutico , Neoplasias Vulvares/veterinária , Neoplasias Vulvares/tratamento farmacológico , Neoplasias Vulvares/patologia , Neoplasias Vulvares/cirurgia , Antineoplásicos Fitogênicos/uso terapêuticoRESUMO
Background: Canine corneal disease is a common condition encountered in daily practice. If the depth of corneal damage is limited to the epithelial layer, healing is often straightforward; however, if it extends into the epithelial basement membrane or corneal parenchyma, surgical treatment is the treatment of choice. Moreover, in cases where there is an underlying disease or where the owner refuses surgical treatment, treatment options are often limited to eye drop treatment, which may be inadequate. Case Description: Dogs aged 10 and 14 years were admitted to the hospital with eye injuries. Based on the examination findings, the owner believed that surgical treatment would be effective; however, this could not be performed owing to the underlying condition of the cases. Hyaluronic acid and antibiotic eye drops were administered, but there was no improvement in the eye damage. The eye-drop treatment was prolonged without any improvement, and in the meantime the patients' weakness became apparent. In parallel with the eye-drop treatment, the patients were given a supplement containing equine placental extract to help restore their physical fitness. Consequently, in addition to the recovery of physical fitness, a film gradually formed over the eye damage area and injuries improved eventually. Conclusion: Based on these cases, supplementation with equine placenta extract may be an effective treatment option for ocular conditions that are difficult to treat surgically.
Assuntos
Lesões da Córnea , Doenças do Cão , Animais , Cães , Doenças do Cão/tratamento farmacológico , Doenças do Cão/cirurgia , Feminino , Cavalos , Lesões da Córnea/veterinária , Lesões da Córnea/tratamento farmacológico , Extratos Placentários/uso terapêutico , Extratos Placentários/administração & dosagem , Masculino , Doenças da Córnea/veterinária , Doenças da Córnea/tratamento farmacológico , Soluções Oftálmicas/uso terapêuticoRESUMO
Background: Gynura procumbens, a well-known traditional herb, has been studied to be an effective chemotherapeutic agent against a wide range of cancer cell types. Case Description: A 7-year-old chihuahua dog was presented to the veterinary teaching hospital with multiple cutaneous MCT grade III masses found on the cranial aspect of the right front leg and the dorsal aspect of the neck/back. Local excision of all cutaneous tumors was performed followed by chemotherapy (vinblastine, prednisone, and cyclophosphamide) every 21-day interval for 9 treatments. Nearby 3 months later, recurrent MCT was observed and lomustine was used instead for 21-day intervals. During the first chemotherapy, the dog had a fever, weak, lethargy, and vomiting. Alternative natural therapy is preferred, the dog has been receiving G. procumbens daily. The dog responded well to this herbal treatment. These recurrent masses began to shrink after a few weeks of treatment. After several months of treatment, all masses were completely gone. Moreover, no micro-metastasis to the lungs, spleen, and liver were detected. Conclusion: This natural herbal was helpful to stop the growth of tumors, to prevent micro-metastasis, and to relieve the patient's symptoms.